Adiso is a clinical stage company advancing an innovative pipeline of novel agents aimed at modulating inflammation.

Dysregulated inflammation is central to many serious diseases and current treatment paradigms are inadequate to stop disease progression. We see a significant opportunity to serve patients with our highly differentiated therapies across a wide range of inflammatory diseases.

We focus on chronic and progressive inflammatory diseases with a high unmet need for targeted therapies